Document Detail

Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer.
MedLine Citation:
PMID:  19496719     Owner:  NLM     Status:  MEDLINE    
Muscle-invasive bladder cancer is a deadly disease that often requires more than radical surgery for optimal management. The best level one evidence supports the use of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy followed by surgery. There remains controversy, however, with some continuing to argue in favor of selective adjuvant chemotherapy only in the highest risk patients. Certain patients and situations argue in favor of a surgery-first approach, with selective chemotherapy in an adjuvant setting. There is a need for better markers for disease risk and progression in advanced bladder cancer to identify those who would benefit the most from aggressive, multimodal therapy. Further studies are needed to address the ongoing questions that remain in the management of this disease.
Peter E Clark
Related Documents :
9507829 - The fate of patients with locally advanced bladder cancer treated conservatively with n...
16146269 - Adjuvant therapy in different risk-groups of patients with superficial bladder cancer.
12118019 - Combined-modality treatment and selective organ preservation in invasive bladder cancer...
25101639 - Correction: medulloblastoma in china: clinicopathologic analyses of shh, wnt, and non-s...
8460449 - Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the blad...
16937309 - Squamous cell carcinoma of the bladder: a patient treated successfully with a new combi...
12712259 - Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-s...
11176049 - Immunohistochemical analysis of metallothionein expression in malignant melanoma in jap...
24590359 - Approximately one-half of patients with early-stage hepatocellular carcinoma meeting mi...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert review of anticancer therapy     Volume:  9     ISSN:  1744-8328     ISO Abbreviation:  Expert Rev Anticancer Ther     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-05     Completed Date:  2009-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101123358     Medline TA:  Expert Rev Anticancer Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  821-30     Citation Subset:  IM    
Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN 37232-2765, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chemotherapy, Adjuvant / methods*
Combined Modality Therapy
Disease Progression
Muscle Neoplasms / drug therapy,  secondary
Neoadjuvant Therapy / methods*
Neoplasm Invasiveness
Risk Factors
Tumor Markers, Biological
Urinary Bladder Neoplasms / drug therapy*,  pathology,  surgery
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Definition and management of patients with bladder cancer who fail BCG therapy.
Next Document:  Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.